Claims for Patent: 9,885,714

Summary for Patent: 9,885,714

Title:	Immunological method for detecting active JCV infection
Abstract:	The invention relates to an immunological method for detecting an extra renal active infection by JC virus in a patient candidate for a treatment with an immunosuppressive treatment or during the course of this treatment.
Inventor(s):	Taoufik; Yassine (Paris, FR)
Assignee:	Assistance Publlque--Hopitaux de Paris (Paris, FR) Universite Paris--Sud 11 (Orsay, FR)
Application Number:	13/254,503
Patent Claims:	1. A method of detecting activated effector helper T lymphocytes against JC virus in a patient, the method comprising: exposing a blood sample from said patient to epitopes of JC virus for a period of time of less than 48 hours; and detecting the presence, in said blood sample, of T lymphocytes re-stimulated in vitro by exposure to said epitopes, which T-lymphocytes are effector helper T lymphocytes that have previously been activated in vivo by JC virus, wherein said detecting is performed by detection of at least one inflammatory cytokine secreted by said T lymphocytes upon presentation of said epitopes of JC virus to said T lymphocytes, said blood sample is taken from a patient who already receives or is set to receive an immunosuppressive treatment. 2. The method of claim 1, wherein said blood sample is exposed to said epitopes by exposing the blood sample to purified JC virus. 3. The method of claim 1, wherein said cytokine is selected from the group consisting of gamma-interferon and interleukin 2. 4. The method of claim 1, wherein said cytokine is detected by ELISA, ELISPOT or flow cytometry. 5. The method of claim 1, wherein said blood sample is a whole blood sample. 6. The method of claim 1, wherein said blood sample is exposed to said epitopes of JC virus for a period of time of less than 24 hours. 7. The method of claim 1, wherein said blood sample is exposed to said epitopes of JC virus for a period of time between 14 and 24 hours. 8. The method of claim 1, further comprising the step of: screening or quantifying for the presence of JC virus in a cerebrospinal fluid sample from said patient. 9. The method of claim 8, wherein said screening or quantifying is performed by PCR or quantitative PCR assay. 10. The method of claim 1, wherein said immunosuppressive treatment is treatment with natalizumab or efalizumab. 11. The method of claim 1, wherein said patient has not yet received immunosuppressive treatment. 12. The method of claim 1, wherein said patient is already receiving an immunosuppressive treatment. 13. The method of claim 12, further comprising monitoring the immunosuppressive treatment of the patient, wherein said immunosuppressive treatment is continued if no activated T-lymphocytes against JC virus are detected in the blood sample of the patient. 14. The method of claim 1, wherein said patient presents a sign or symptom of Progressive Multi-focal Leukoencephalopathy.

Details for Patent 9,885,714

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RAPTIVA	efalizumab	Injection	125075	10/27/2003		2029-03-03
Biogen Inc.	TYSABRI	natalizumab	Injection	125104	11/23/2004		2029-03-03